Mechanisms of anticancer drug action

Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases

Volumn , Issue , 2005, Pages 31-55

  Wesselborg, Sebastian ^a   Lauber, Kirsten ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900875977     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-23695-3_2     Document Type: Chapter

References (261)

1. Adams JM & Cory S. (1998). The Bcl-2 protein family: arbiters of cell survival. Science, 281:1322-6.
2. Adida C, Berrebi D, Peuchmaur M, et al, (1998). Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet, 351:882-3.
3. Adida C, Recher C, Raffoux E, et al, (2000). Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol, 111:196-203.
4. Allison J, Georgiou HM, Strasser A & Vaux DL. (1997). Transgenic expression of CD95 ligand on islet b-cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl AcadSci USA, 94:3943-7.
5. Altieri DC. (2001). The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med, 7:542-7.
6. Altieri DC. (2003a). Survivin and apoptosis control. Adv Cancer Res, 88:31-52.
7. Altieri DC. (2003b). Validating survivin as a cancer therapeutic target. Nat Rev Cancer, 3:46-54.
8. Arai H, Gordon D, Nabel EG & Nabel GJ. (1997). Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA, 94:13862-7.
9. Arnt CR, Chiorean MV, Heldebrant MP, et al, (2002). Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAPl in situ. J Biol Chem, 277:44236-43.
10. Ashkenazi A, Pai RC, Fong S, et al., (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest, 104:155-62.
11. Attardi LD, Reczek EE, Cosmas C, et al., (2000). PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev, 14:704-18.
12. Ballestrero A, Nencioni A, Boy D, et al, (2004). Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. Clin Cancer Res, 10:1463-70.
13. Banerjee D. (2001). Genasense (Genta fnc). Curr Opin Investig Drugs, 2:574-80.
14. Bantel H, Engels IH, Voelter W, et al, (1999). Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res, 59:2083-90.
15. Bargou RC, Daniel PT, Mapara MY, et al, (1995). Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer, 60:854-9.
16. Behrens CK, Igney FH, Arnold B, et al, (2001). CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice. J Immunol, 166:3240-7.
17. Belka C, Schmid B, Marini P, et al, (2001). Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene, 20:2190-6.
18. Bellgrau D, Gold D, Selawry H, et al, (1995). A role for CD95 ligand in preventing graft rejection. Nature, 377:630-2.
19. Beltinger C, Fulda S, Kammertoens T, et al, (1999). Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc Natl Acad Sci USA, 96:8699-704.
20. Bennett M, Macdonald K, Chan SW, et al, (1998a). Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science, 282:290-3.
21. Bennett MW, O'Connell J, O'Sullivan GC, et al, (1998b). The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol, 160:5669-75.
22. Bergamaschi D, Gasco M, Hiller L, et al, (2003). p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3:387-102.
23. Blagosklonny MV. (2002). P53: an ubiquitous target of anticancer drugs. Int J Cancer, 98:161-6.
24. Boesen-de Cock JG, de Vries E, et al, (1998). The anti-cancer drug etoposide can induce caspase-8 processing and apoptosis in the absence of CD95 receptor-ligand interaction. Apoptosis, 3:17-25.
25. Bull EK, Chakrabarty S, Brodsky I & Haines DS. (1998). mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells. Oncogene, 16:2249-57.
26. Byun DS, Cho K, Ryu BK, et al, (2003). Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17pl3.2 locus, in human gastric adenocarcinomas. Cancer Res, 63:7068-75.
27. Cain K, Brown DG, Langlais C & Cohen GM. (1999). Caspase activation involves the formation of the aposome, a large (approximately 700 kDa) caspase-activating complex. J Biol Chem, 274:22686-92.
28. Campos L, Rouault JP, Sabido O, et al, (1993). High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81:3091-6.
29. Chi KN, Gleave ME, Klasa R, et al, (2001). A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res, 7:3920-7.
30. Chinnaiyan A M, Prasad U, Shankar S, et al, (2000). Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA, 97:1754-9.
31. Chipuk JE & Green DR. (2003). p53's believe it or not: lessons on transcription-independent death. J Clin Immunol, 23:355-61.
32. Chipuk JE, Kuwana T, Bouchier-Hayes L, et al, (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science, 303:1010-14.
33. Chipuk JE, Maurer U, Green DR & Schuler M. (2003). Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4, 371-381.
34. Clarke AR, Purdie CA, Harrison DJ, et al, (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature, 362:849-52.
35. Cole SP, Bhardwaj G, Gerlach JH, et al, (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258:1650-4.
36. Contente A, Dittmer A, Koch MC, et al, (2002). A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat Genet, 30:315-20.
37. Cotter FE, Johnson P, Hall P, et al, (1994). Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene, 9:3049-55.
38. Cryns V & Yuan J. (1998). Proteases to die for. Genes Dev, 12:1551-70.
39. Daniel PT, Schulze-Osthoff K, Belka C & Guner D. (2003). Guardians of cell death: the Bcl-2 family proteins. Essays Biochem, 39:73-88.
40. Datta R, Oki E, Endo K, et al. (2000). XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. J Biol Chem, 275:31733-8.
41. Debatin KM (2004) Apoptosis pathways in cancer and cancer therapy. Cane ImmunolImmunother, 53:153-9.
42. Debatin KM & Krammer PH. (2004). Death receptors in chemotherapy and cancer. Oncogene, 23:2950-66.
43. Degterev A, Boyce M & Yuan J. (2003). A decade of caspases. Oncogene, 22:8543-67.
44. Deng, Y & Wu X. (2000). Peg3/Pwl promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci USA, 97:12050-5.
45. Deveraux QL & Reed JC. (1999). IAP family proteins-suppressors of apoptosis. Genes Dev, 13:239-52.
46. Dhein J, Walzcak H, Baumler C, et al, (1995). Autocrine T-cell suicide mediated by APO-l/(Fas/CD95). Nature, 373:438-41.
47. Du C, Fang M, Li Y, et al, (2000). Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating LAP inhibition. Cell, 102:33-42.
48. Eichhorst ST, Muerkoster S, Weigand MA & Krammer PH. (2001). The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-l/Fas) system. Cancer Res, 61:243-8.
49. Eichhorst ST, Muller M, Li-Weber M, et al, (2000). A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol, 20:7826-37.
50. Eischen CM, Kottke TJ, Martins LM, et al, (1997). Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood, 90:935-3.
51. Enari M, Sakahiera H, Yokoyama H, et al, (1998). A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature, 391:43-50.
52. Engels IH, Stepczynska A, Stroh C, et al, (2000). Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene, 19:4563-73.
53. Ferguson TA, Green DR & Griffith TS (2002). Cell death and immune privilege. Int Rev Immunol, 21:153-72.
54. Ferrari D, Stepczynska A, Los M, et al, (1998). Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95-and anticancer drug-induced apoptosis. J Exp Med, 188:979-84.
55. Ferri KF & Kroemer G. (2001). Organelle-specific initiation of cell death pathways. Nat Cell Biol, 3:E255-63.
56. Fischer U, Janicke RU & Schulze-Osthoff, K. (2003). Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ, 10:76-100.
57. French LE & Tschopp J. (2002). Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol, 12:51-5.
58. Friesen C, Fulda S & Debatin KM. (1999). Cytotoxic drugs and the CD95 pathway. Leukemia, 13:1854-8.
59. Friesen C, Herr I, Krammer PH & Debatin KM. (1996). Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med, 2:574-7.
60. Fuchs EJ, McKenna KA & Bedi A. (1997). p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta. Cancer Res, 57:2550-4.
61. Fulda S, Friesen C, Los M, et al, (1997a). Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res, 57:4956-64.
62. Fulda S, Los M, Friesen C & Debatin KM. (1998a). Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer, 76:105-14.
63. Fulda S, Meyer E, Friesen C, et al, (2001). Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene, 20:1063-75.
64. Fulda, S., Scaffidi, C, Pietsch, T., et al, (1998b). Activation of the CD95 (APO-1/Fas) pathway in drug-and gamma-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ, 5:884-93.
65. Fulda S, Sieverts H, Friesen C, et al, (1997b). The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res, 57:3823-9.
66. Fulda S, Strauss G, Meyer E & Debatin KM. (2000). Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood, 95:301-8.
67. Fulda S, Susin SA, Kroemer G & Debatin KM. (1998c). Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res, 58:4453-60.
68. Fulda S, Wick W, Weller M, et al, (2002). Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med, 8:808-15.
69. Furuhata T, Tokino T, Urano T & Nakamura Y. (1996). Isolation of a novel GPI-anchored gene specifically regulated by p53; correlation between its expression and anti-cancer drug sensitivity. Oncogene, 13:1965-70.
70. Gamen S, Anel A, Lasierra P, et al, (1997). Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBSLett, 417:360-4.
71. Glaser T, Wagenknecht B, Groscurth P, et al, (1999). Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells. Oncogene, 18:5044-53.
72. Gliniak B & Le T. (1999). Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res, 59:6153-8.
73. Goltsev YV, Kovalenko AV, Arnold E, et al, (1997). CASH, a novel caspase homologue with death effector domains. J Biol Chem, 272:19641-4.
74. Goyal L. (2001). Cell death inhibition: keeping caspases in check. Cell, 104:805-8.
75. Green DR. (2000). Apoptotic pathways: paper wraps stone blunts scissors. Cell, 102:1-4.
76. Green DR & Ferguson TA (2001) The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2:917-24.
77. Griffith TS, Brunner T, Fletcher SM, et al, (1995). Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 270:1189-92.
78. Griffith TS, Yu X, Herndon JM, et al, (1996). CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity, 5:7-16.
79. Guner D, Belka C & Daniel PT. (2003). Disruption of cell death signaling in cancer: impact on disease prognosis and response to therapy. Curr Med Chem Anti-Cane Agents, 3:319-26.
80. Guo F, Nimmanapalli R, Paranawithana S, et al., (2002). Fxtopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood, 99:3419-26.
81. Hahne M, Rimoldi D, Schroter M, et al, (1996). Melanoma cell expression of Fas (Apo-l/CD95) ligand: implications for tumor immune escape. Science, 274:1363-6.
82. Hakem R, Hakem A, Duncan GS, et al, (1998). Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell, 94:339-52.
83. Haldar S, Negrini M, Monne M, et al, (1994). Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res, 54:2095-7.
84. Hegde R, Srinivasula SM, Zhang Z, et al., (2002). Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem, 277:432-8.
85. Herr I, Posovszky C, Di Marzio LD, et al., (2000). Autoamplification of apoptosis following ligation of CD95-L, TRAIL and TNF-a. Oncogene, 19:4255-62.
86. Herr I, Wilhelm D, Bohler T, et al., (1997). Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBOJ, 16:6200-8.
87. Hoffman WH, Biade S, Zilfou JT, et al., (2002). Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem, 277:3247-57.
88. Holcik M & Korneluk RG. (2001). XIAP, the guardian angel. Nat Rev Mol Cell Biol, 2:550-6.
89. Hollstein M, Sidransky D, Vogelstein B & Harris CC. (1991). p53 mutations in human cancers. Science, 253:49-53.
90. Houghton JA, Harwood FG & Tillman DM. (1997). Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc Natl Acad Sci USA, 94:8144-9.
91. Hu S, Vincenz C, Ni J, et al, (1997). I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1-and CD95-induced apoptosis. J Biol Chem, 272:17255-7.
92. Hu Y, Benedict MA, Ding L & Nunez G. (1999). Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis. EMBOJ, 18:3586-95.
93. Ichikawa K, Liu W, Zhao L, et al, (2001). Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med, 7:954-60.
94. Igney FH, Behrens CK & Krammer PH. (2000). Tumor counterattack- concept and reality. Eur J Immunol, 30:725-31.
95. Igney FH & Krammer PH. (2002). Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer, 2:277-88.
96. Ihrie RA & Attardi LD. (2004). Perp-etrating p53-Dependent Apoptosis. Cell Cycle, 3:267-9.
97. Ihrie RA, Reczek E, Horner JS, et al, (2003). Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol, 13:1985-90.
98. Irmler M, Thome M, Hahne M, et al, (1997). Inhibition of death receptor signals by cellular FLIP. Nature, 388:190-5.
99. Irwin MS, Kondo K, Marin MC, et al, (2003). Chemosensitivity linked to p73 function. Cancer Cell, 3:403-10.
100. Israeli D, Tessler E, Haupt Y, et al, (1997). A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBOJ, 16:4384-92.
101. Janicke RU, Sprengart ML, Wati MR & Porter AG. (1998). Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem, 273:9357-60.
102. Jo M, Kim TH, Seol DW, et al, (2000). Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med, 6:564-7.
103. Johnson MD, Wu X, Aithmitti N & Morrison RS. (2002). Peg3/Pwl is a mediator between p53 and Bax in DNA damage-induced neuronal death. J Biol Chem, 277:23000-7.
104. Johnstone RW, Ruefli AA & Lowe SW. (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108:153-64.
105. Joseph B, Ekedahl J, Sirzen F, et al, (1999). Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. Biochem Biophys Res Commun, 262:381-7.
106. Kagawa K, Inoue T, Tokino T, et al, (1997). Overexpression of GML promotes radiation-induced cell cycle arrest and apoptosis. Biochem Biophys Res Commun, 241:481-5.
107. Kang SM, Hoffmann A, Le D, et al, (1997a). Immune response and myoblasts that express Fas ligand. Science, 278:1322-4.
108. Kang SM, Schneider DB, Lin Z, et al, (1997b). Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med, 3:738-43.
109. Kanwar JR, Shen WP, Kanwar RK, et al, (2001). Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst, 93:1541-52.
110. Kasibhatla S, Brunner T, Genestier L, et al, (1998). DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-k B and AP-1. Mol Cell, 1:543-51.
111. Kaufmann SH & Earnshaw WC. (2000). Induction of apoptosis by cancer chemotherapy. Exp Cell Res, 256:42-9.
112. Kaufmann SH & Vaux DL. (2003). Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene, 22:7414-30.
113. Keane MM, Rubinstein Y, Cuello M, et al, (2000). Inhibition of NF-kB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat, 64:211-19.
114. Khanna KK & Jackson SP. (2001). DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet, 27:247-54.
115. Kharbanda S, Pandey P, Schofield L, et al, (1997). Role of Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci USA, 94:6939-12.
116. Kimura Y, Furuhata T, Shiratsuchi T, et al, (1997). GML sensitizes cancer cells to Taxol by induction of apoptosis. Oncogene, 15:1369-74.
117. Kluck RM, Bossy-Wetzel E, Green DR & Newmeyer DD. (1997). The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science, 275:1132-6.
118. Konishi A, Shimizu S, Hirota J, et al, (2003). Involvement of histone HI.2 in apoptosis induced by DNA double-strand breaks. Cell, 114:673-88.
119. Kroemer G & Reed JC. (2000). Mitochondrial control of cell death. Nat Med, 6:513-19.
120. Landowski TH, Shain KH, Oshiro MM, et al, (1999). Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood, 94:265-74.
121. Lassus P, Opitz-Araya X & Lazebnik Y. (2002). Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science, 297:1352-4.
122. Lawrence D, Shahrokh Z, Marsters S, et al, (2001). Differential hepatocyte toxicity of recombinant Apo217TRAIL versions. Nat Med, 7:383-5.
123. LeBlanc HN & Ashkenazi A. (2003). Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ, 10:66-75.
124. Li H, Kolluri SK, Gu J, et al, (2000). Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science, 289:1159-64.
125. Li H, Zhu H, Xu C-J & Yuan J. (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94:491-501.
126. Li J, Feng Q, Kim JM, et al, (2001a). Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology, 142:370-80.
127. Li LY, Luo, X & Wang X. (2001b). Endonuclease G is an apoptotic DNase when released from mitochondria. Nature, 412:95-9.
128. Li P, Nijhawan D, Budihardjo I, et al, (1997). Cytochrome c and dATP-dependent formation of Apaf-l/Caspase-9 complex initiates an apoptotic protease cascade. Cell, 91:479-89.
129. Lin Y, Ma W & Benchimol S. (2000). Pidd, a new death-domain- containing protein, is induced by p53 and promotes apoptosis. Nat Genet, 26:122-7.
130. Liston P, Fong WG, Kelly NL, et al, (2001). Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol, 3:128-33.
131. Liu X, Zou H, Slaughter C & Wang X. (1997). DFF, a heterodimeric protein that functions downstream of caspase 3 to trigger DNA fragmentation during apoptosis. Cell, 89:175-84.
132. Los M, Herr I, Friesen C, et al, (1997). Cross-resistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood, 90:3118-29.
133. Los M, Wesselborg S & Schulze-Osthoff K. (1999). The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity, 10:629-39.
134. Lowe SW, Bodis S, McClatchey A, et al, (1994). p53 status and the efficacy of cancer therapy in vivo. Science, 266:807-10.
135. Lowe SW, Ruley HE, Jacks T & Housman DE. (1993a). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74:957-67.
136. Lowe SW, Schmitt EM, Smith SW, et al, (1993b). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362:847-9.
137. Luo X, Budihardjo I, Zou H, et al, (1998). Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94:481-90.
138. Mandic A, Hansson J, Linder S & Shoshan MC. (2003). Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem, 278:9100-06.
139. Marchenko ND, Zaika A & Moll UM. (2000). Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem, 275:16202-12.
140. Marcucci G, Byrd JC, Dai G, et al, (2003). Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood, 101:425-32.
141. Marks PA, Richon VM, Breslow R & Rifkind RA. (2001). Histone deacetylase inhibitors as new cancer drugs. CurrOpin Oncol, 13:477-83.
142. Martin DA, Siegel RM, Zheng L & Lenardo MJ. (1998). Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalphal) death signal. J Biol Chem, 273:4345-9.
143. Martinou JC & Green DR. (2001). Breaking the mitochondrial barrier. NatRevMol Cell Biol, 2:63-7.
144. Martins LM, Iaccarino I, Tenev T, et al, (2002). The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem, 277:439-44.
145. Matsuda K, Yoshida K, Taya Y, et al, (2002). p53AIPl regulates the mitochondrial apoptotic pathway. Cancer Res, 62:2883-9.
146. Micheau O, Hammann A, Solary E & Dimanche-Boitrel MT. (1999a). STAT-1-independent upregulation of FADD and procaspase-3 and-8 in cancer cells treated with cytotoxic drugs. Biochem Biophys Res Commun, 256:603-7.
147. Micheau O, Solary E, Hammann A & Dimanche-Boitrel MT. (1999b). Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem, 274:7987-92.
148. Minn AJ, Rudin CM, Boise LH & Thompson CB. (1995). Expression of bcl-xL can confer a multidrug resistance phenotype. Blood, 86:1903-10.
149. Miyashita T, Krajewski S, Krajewska M, et al, (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9:1799-805.
150. Miyashita T & Reed JC. (1993). Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81:151-7.
151. Miyashita T & Reed JC. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80:293-9.
152. Moroni MC, Hickman ES, Denchi EL, et al, (2001). Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol, 3:552-8.
153. Morris MJ, Tong WP, Cordon-Cardo C, et al, (2002). Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res, 8:679-83.
154. Muller M, Strand S, Hug H, et al, (1997). Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (Apo-1/Fas receptor/ligand system and involves activation of wild-type p53. J Clin Invest, 99:403-13.
155. Muller M, Wilder S, Bannasch D, et al, (1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med, 188:2033-45.
156. Murphy M, Hinman A & Levine AJ. (1996). Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev, 10:2971-80.
157. Muzio M, Stockwell BR, Stennicke HR, et al, (1998). An induced proximity model for caspase-8 activation. J Biol Chem, 273:2926-30.
158. Nagane M, Pan G, Weddle JJ, et al, (2000). Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res, 60:847-53.
159. Nakagawa T, Zhu H, Morishima N, et al, (2000). Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature, 403:98-103.
160. Nakano K. & Vousden KH. (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell, 7:683-94.
161. Nencioni A, Lauber K, Grunebach F, et al, (2003). Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling. J Immunol, 171:5148-56.
162. Newton K. & Strasser A. (2000). Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling. Implications for cancer therapy. J Exp Med, 191:195-200.
163. Niehans GA, Brunner T, Frizelle SP, et al, (1997). Human lung carcinomas express Fas ligand. Cancer Res, 57:1007-12.
164. Nitsch R, Bechmann I, Deisz RA, et al, (2000). Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet, 356:827-8.
165. Norbury CJ & Zhivotovsky B. (2004). DNA damage-induced apoptosis. Oncogene, 23:2797-808.
166. Nygren P & Larsson R. (2003). Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med, 253:46-75.
167. O'Connell J, Bennett MW, O'Sullivan GC, et al, (1999). Fas counter-attack-the best form of tumor defense? Nat Med, 5:267-8.
168. O'Connell J, O'Sullivan GC, Collins JK & Shanahan F. (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med, 184:1075-82.
169. Oda E, Ohki R, Murasawa H, et al, (2000a). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science, 288:1053-8.
170. Oda K, Arakawa H, Tanaka T, et al, (2000b). p53AIPl, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell, 102:849-62.
171. Olie RA, Hafner C, Kuttel R, et al, (2002). Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol, 118:505-12.
172. Palissot V, Belhoussine R, Carpentier Y, et al, (1998). Resistance to apoptosis induced by topoisomerase I inhibitors in multidrug-resistant HL60 leukemic cells. Biochem Biophys Res Commun, 245:918-22.
173. Paulsen M & Ferguson-Smith AC. (2001). DNA methylation in genomic imprinting, development, and disease. J Pathol, 195:97-110.
174. Perkins CL, Fang G, Kim CN & Bhalla KN. (2000). The role of Apaf-1, caspase-9, and bid proteins in etoposide-or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res, 60:1645-53.
175. Persidis A. (1999). Cancer multidrug resistance. Nat Biotechnol, 17:94-5.
176. Petros AM, Gunasekera A, Xu N, et al, (2004). Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBSLett, 559:171-4.
177. Polyak K, Xia Y, Zweier JL, et al, (1997). A model for p53-induced apoptosis. Nature, 389:300-5.
178. Prokop A, Wieder T, Sturm I, et al, (2000). Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia, 14:1606-13.
179. Puthalakath H & Strasser A. (2002). Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ, 9:505-12.
180. Reczek EE, Flores ER, Tsay AS, et al, (2003). Multiple response elements and differential p53 binding control Perp expression during apoptosis. Mol Cancer Res, 1:1048-57.
181. Reed JC. (1999). Dysregulation of apoptosis in cancer. J Clin Oncol, 17:2941-53.
182. Reed JC & Bischoff JR. (2000). BIRinging chromosomes through cell division-and survivin' the experience. Cell, 102:545-8.
183. Relaix F, Wei X, Li W, et al, (2000). Pwl/Peg3 is a potential cell death mediator and cooperates with Siahla in p53-mediated apoptosis. Proc Natl Acad Sci USA, 97:2105-10.
184. Restifo NP. (2000). Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med, 6:493-5.
185. Restifo NP. (2001). Countering the 'counterattack' hypothesis. Nat Med, 7:259.
186. Rich, T., Allen, R. L., and Wyllie, A. H. (2000). Defying death after DNA damage. Nature 407, 777-783.
187. Robertson JD, Enoksson M, Suomela M, et al, (2002). Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem, 277:29803-9.
188. Robertson JD, Gogvadze V, Zhivotovsky B & Orrenius S. (2000). Distinct pathways for stimulation of cytochrome c release by etoposide. J Biol Chem, 275:32438-43.
189. Rodicker F & Putzer BM. (2003). p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Res, 63:2737-41.
190. Rohn TA, Wagenknecht B, Roth W, et al, (2001). CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene, 20:4128-37.
191. Rudin, C. M., Kozloff, M., Hoffman, P. C, Edelman, M. J., Karnauskas, R., Tomek, R., Szeto, L., and Vokes, E. E. (2004). Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22, 1110-1117.
192. Rudin CM, Otterson GA, Mauer AM, et al, (2002). A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol, 13:539-45.
193. Saas P, Walker PR, Hahne M, et al, (1997). Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest, 99:1173-8.
194. Salvesen GS, & Duckett CS. (2002). LAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol, 3:401-10.
195. Scaffidi C, Fulda S, et al, (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBOJ, 17:1675-87.
196. Schuler M, Bossy-Wetzel E, Goldstein JC, et al, (2000). p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem, 275:7337-42.
197. Schuler M, Maurer U, Goldstein JC, et al, (2003). p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ, 10:451-60.
198. Schulze-Bergkamen H, et al, (2004). Apoptosis in cancer-implications for therapy. Semin Oncol, 31:90-119.
199. Schulze-Osthoff K, et al. (1998) Apoptosis signaling by death receptors. Eur J Biochem, 254:439-59.
200. Scott CL, Schuler M, Marsden VS, et al, (2004). Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation. J Cell Biol, 164:89-96.
201. Shiraki K, Tsuji N, Shioda T, et al, (1997). Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA, 94:6420-5.
202. Slee EA, Adrain C & Martin SJ. (1999a). Serial killers: ordering caspase activation events in apoptosis. Cell Death Differ, 6:1067-74.
203. Slee EA, Harte MT, Kluck RM, et al, (1999b). Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2,-3,-6,-7,-8, and-10 in a caspase-9-dependent manner. J Cell Biol, 144:281-92.
204. Slee EA, Keogh SA & Martin SJ. (2000). Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ, 7:556-65.
205. Slee EA, O'Connor DJ & Lu X. (2004). To die or not to die: how does p53 decide? Oncogene, 23:2809-18.
206. Soengas MS, Alarcon RM, Yoshida H, et al, (1999). Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science, 284:156-9.
207. Soengas MS, Capodieci P, Polsky D, et al, (2001). Lnactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 409:207-11.
208. Soussi T (2003) p53 mutations and resistance to chemotherapy: A stab in the back for p73. Cane Cell, 3:303-5.
209. Soussi T & Beroud C. (2001). Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer, 1:233-40.
210. Srinivasula SM, Ahmad M, Fernandes-Alnemri T & Alnemri ES. (1998). Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell, 1:949-57.
211. Srinivasula SM, Ahmad M, Ottilie S, et al, (1997). FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFRl-induced apoptosis. J Biol Chem, 272:18542-5.
212. Strand S, Hofmann WJ, Hug H, et al, (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat Med, 2:1361-6.
213. Strasser A, Harris AW, Huang DC, et al, (1995). Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBOJ, 14:6136-47.
214. Strasser A, Harris AW, Jacks T & Cory S. (1994). DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell, 79:329-39.
215. Sturm I, Kohne CH, Wolff G, et al, (1999). Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol, 17:1364-74.
216. Sturm I, Petrowsky H, Volz R, et al, (2001). Analysis of p53/BAX/pl6(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and pl6(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol, 19:2272-81.
217. Suliman A, Lam A, Datta R & Srivastava, RK. (2001). Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and-independent pathways. Oncogene, 20:222.
218. Susin SA, Lorenzo HK, Zamzami N, et al, (1999). Molecular characterization of mitochondrial apoptosis-inducing factor. Nature, 397:441-6.
219. Takakura M, Kyo S, Sowa Y, et al, (2001). Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res, 29:3006-11.
220. Takimoto R & El-Deiry WS. (2000). Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene, 19:1735-43.
221. Tamm I, Kornblau SM, Segall H, et al, (2000). Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res, 6:1796-803.
222. Tamm I, Trepel M, Cardo-Vila M et al (2003) Peptides targeting caspase inhibitors. J Biol Chem 278:14401-5.
223. Tanaka M, Suda T, Haze K, et al, (1996). Fas ligand in human serum. Nature Med, 2:317-22.
224. Tang D, Lahti, J. M & Kidd VJ. (2000). Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem, 275:9303-7.
225. Teitz T, Wei T, Valentine MB, et al, (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med, 6:529-35.
226. Thornberry NA & Lazebnik Y. (1998). Caspases: enemies within. Science, 281:1312-6.
227. Tinel A & Tschopp J. (2004). The PIDDosome, a Protein Complex Implicated in Activation of Caspase-2 in Response to Genotoxic Stress. Science, 304:843-6.
228. Tokino T & Nakamura Y. (2000). The role of p53-targets in human cancer. Crit Rev Oncol Hematol, 33:1-6.
229. Tokino T, Thiagalingam S, el-Deiry WS, et al, (1994). p53 tagged sites from human genomic DNA. Hum Mol Genet, 3:1537-42.
230. Tolomeo M, Dusonchet L, Meli M, et al, (1998). The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ, 5:735-42.
231. Urano T, Nishimori H, Han H, et al (1997). Cloning of P2XM, a novel human P2X receptor gene regulated by p53. Cancer Res, 57:3281-7.
232. Van De Donk NW, De Weerdt O, Veth G, et al, (2004). G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia, (in press)
233. van Loo G, van Gurp M, Depuydt B, et al, (2002). The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity. Cell Death Differ, 9:20-6.
234. Varfolomeev EE, Schuchmann M, Luria V, et al, (1998). Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apol, and DR3 and is lethal prenatally. Immunity, 9:267-76.
235. Venot C, Maratrat M, Dureuil C, et al, (1998). The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBOJ, 17:4668-79.
236. Verhagen AM, Ekert PG, Pakusch M, et al, (2000). Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell, 102:43-53.
237. Villunger A, Egle A, Kos M, et al, (1997a). Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-l/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res, 57:3331-4.
238. Villunger A, Egle A, Marschitz I, et al, (1997b). Constitutive expression of Fas (Apo-l/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood, 90:12-20.
239. Villunger A, Michalak EM, Coultas L, et al, (2003). p53-and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science, 302:1036-8.
240. Villunger A, & Strasser A. (1998). Does "death receptor" signaling play a role in tumorigenesis and cancer therapy? Oncol Res, 10:541-50.
241. Villunger A, & Strasser A. (1999). The great escape: is immune evasion required for tumor progression? Nat Med, 5:874-5.
242. Vogelstein B, Lane D, & Levine AJ. (2000). Surfing the p53 network. Nature, 408:307-10.
243. Wajant H, Pfizenmaier K, & Scheurich P. (2002), TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis, 7:449-59.
244. Walczak H, Miller RE, Ariail K, et al, (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 5:157-63.
245. Waters JS, Webb A, Cunningham D, et al, (2000). Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol, 18:1812-23.
246. Webb A, Cunningham D, Cotter F, et al, (1997). BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349:1137-41.
247. Wesselborg S, Engels IH, Rossmann E, et al, (1999). Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood, 93:3053-63.
248. Wieder T, Essmann F, Prokop A, et al, (2001). Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood, 97:1378-87.
249. Wu GS, Burns TF, McDonald ER, et al, (1997a). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet, 17:141-3.
250. Wu Q, Li Y, Liu.R, et al, (1997b). Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization. EMBOJ, 16:1656-69.
251. Xia C, Xu Z, Yuan X, et al, (2002). Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther, 1:687-94.
252. Yan N, & Shi Y. (2003). Histone HI.2 as a trigger for apoptosis. Nat Struct Biol, 10:983-985.
253. Yang J, Liu X, Bhalla K, et al, (1997). Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science, 275:1129-32.
254. Yang L, Mashima T, Sato S, et al., (2003). Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smacpeptide. CancerRes, 63:831-7.
255. Yang XH, Sladek TL, Liu X, Butler BR, et al, (2001). Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin-and etoposide-induced apoptosis. CancerRes, 61:348-54.
256. Yeh WC, Pompa JL, McCurrach ME, et al, (1998). FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science, 279:1954-8.
257. Yoneda T, Imaizumi K, Oono K, et al, (2001). Activation of caspase-12, an endoplastic reticulum resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress. J Biol Chem, 276:13935-40.
258. Yoshida H, Kong YY, Yoshida R, et al, (1998). Apafl is required for mitochondrial pathways of apoptosis and brain development. Cell, 94:739-50.
259. Yu J, Zhang L, Hwang PM, et al, (2001). PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7:673-82.
260. Zhang L, Yu J, Park BH, et al, (2000). Role of BAX in the apoptotic response to anticancer agents. Science, 290:989-92.
261. Ziegler A, Luedke GH, Fabbro, D, et al, (1997). Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst, 89:1027-36.